TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's
LONDON TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease.
The study in Pick's, or behavioral-variant frontotemporal dementia (bvFTD), is due to be followed by a Phase III trial of LMTX in Alzheimer's. Funding for both trials is in place.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST